$NTRB
NutriBand Inc. Stock $ntrb

$ntrb Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000121390024037996 Filed on May 01, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2024
Revenue	$408.5K	$524.6K	$2.085M
YoY Change	-14.34%	-0.56%	0.27%
Cost Of Revenue	$243.7K	$343.4K	$1.223M
YoY Change	-4.28%	-13.75%	-7.97%
Gross Profit	$164.8K	$181.2K	$862.1K
YoY Change	-25.87%	40.05%	14.89%
Gross Profit Margin	40.34%	34.54%	41.34%
Selling, General & Admin	$1.080M	$924.2K	$3.774M
YoY Change	28.58%	-22.32%	-3.64%
% of Gross Profit	655.23%	509.99%	437.72%
Research & Development	$974.5K	$563.4K	$1.960M
YoY Change	143.37%	90.44%	99.59%
% of Gross Profit	591.39%	310.88%	227.4%
Depreciation & Amortization	$69.10K	$69.32K	$287.7K
YoY Change	-8.11%	-6.59%	-12.85%
% of Gross Profit	41.93%	38.25%	33.37%
Operating Expenses	$2.054M	$1.488M	$5.734M
YoY Change	65.64%	0.13%	17.06%
Operating Profit	-$1.889M	-$1.306M	-$4.872M
YoY Change	85.63%	-3.68%	8.87%
Interest Expense	$8.618K	-$20.19K	$75.82K
YoY Change	225.21%	-578.44%	-1014.54%
% of Operating Profit
Other Income/Expense, Net	-$8.600K		-$613.4K
YoY Change	-424.65%		-111.74%
Pretax Income	-$1.898M	-$1.881M	-$5.485M
YoY Change	86.96%	12.01%	22.35%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$1.898M	-$1.881M	-$5.485M
YoY Change	86.96%	12.01%	22.35%
Net Earnings / Revenue	-464.61%	-358.55%	-263.04%
Basic Earnings Per Share	-$0.21		-$0.69
Diluted Earnings Per Share	-$0.21	-$0.23	-$0.69
COMMON SHARES
Basic Shares Outstanding	10.97M shares		7.954M shares
Diluted Shares Outstanding	9.160M shares		7.954M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.348M	$492.9K	$492.9K
YoY Change	553.15%	-75.17%	-75.17%
Cash & Equivalents	$8.348M	$492.9K	$492.9K
Short-Term Investments
Other Short-Term Assets	$128.6K	$211.7K	$211.7K
YoY Change	-65.19%	-42.16%	-42.16%
Inventory	$168.5K	$168.6K	$168.6K
Prepaid Expenses	$128.6K	$211.7K
Receivables	$85.14K	$148.6K	$148.7K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.730M	$1.022M	$1.022M
YoY Change	337.92%	-62.07%	-62.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$740.3K	$774.9K	$806.3K
YoY Change	-13.26%	-13.68%	-16.05%
Goodwill	$5.022M	$5.022M
YoY Change	0.0%	0.0%
Intangibles	$639.0K	$667.3K
YoY Change	-15.04%	-14.5%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.425M	$6.495M	$6.495M
YoY Change	-3.86%	-3.95%	-3.95%
TOTAL ASSETS
Total Short-Term Assets	$8.730M	$1.022M	$1.022M
Total Long-Term Assets	$6.425M	$6.495M	$6.495M
Total Assets	$15.15M	$7.517M	$7.517M
YoY Change	74.68%	-20.51%	-20.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$994.1K	$680.1K	$680.1K
YoY Change	82.82%	27.2%	27.2%
Accrued Expenses	$25.99K	$34.28K	$34.28K
YoY Change	-18.81%	9.56%	9.56%
Deferred Revenue		$157.5K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$127.4K	$127.2K	$127.2K
YoY Change	539.34%	544.28%	544.28%
Total Short-Term Liabilities	$1.417M	$999.1K	$999.1K
YoY Change	80.63%	33.46%	33.46%
LONG-TERM LIABILITIES
Long-Term Debt	$374.5K	$79.83K	$79.83K
YoY Change	157.52%	-20.57%	-20.57%
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$374.5K	$79.83K	$79.83K
YoY Change	118.46%	-40.77%	-40.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.417M	$999.1K	$999.1K
Total Long-Term Liabilities	$374.5K	$79.83K	$79.83K
Total Liabilities	$1.791M	$1.079M	$1.079M
YoY Change	87.42%	22.13%	22.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$29.88M	-$27.98M
YoY Change	27.09%	24.38%
Common Stock	$10.96K	$8.860K
YoY Change	39.92%	13.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$32.64K	$32.64K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$13.36M	$6.438M	$6.438M
YoY Change
Total Liabilities & Shareholders Equity	$15.15M	$7.517M	$7.517M
YoY Change	74.68%	-20.51%	-20.51%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2024
OPERATING ACTIVITIES
Net Income	-$1.898M	-$1.881M	-$5.485M
YoY Change	86.96%	12.01%	22.35%
Depreciation, Depletion And Amortization	$69.10K	$69.32K	$287.7K
YoY Change	-8.11%	-6.59%	-12.85%
Cash From Operating Activities	-$833.9K	-$718.2K	-$3.528M
YoY Change	11.21%	-11.77%	18.09%
INVESTING ACTIVITIES
Capital Expenditures	$6.195K	$49.16K	$51.76K
YoY Change	136.09%	390.62%	-34.73%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$6.195K	-$49.16K	-$51.76K
YoY Change	136.09%	390.62%	-34.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$8.695M	-5.030K	$2.087M
YoY Change	19169.37%	-26.57%	1203.63%
NET CHANGE
Cash From Operating Activities	-$833.9K	-718.2K	-$3.528M
Cash From Investing Activities	-$6.195K	-49.16K	-$51.76K
Cash From Financing Activities	$8.695M	-5.030K	$2.087M
Net Change In Cash	$7.855M	-772.4K	-$1.492M
YoY Change	-1210.43%	-7.04%	-48.65%
FREE CASH FLOW
Cash From Operating Activities	-$833.9K	-$718.2K	-$3.528M
Capital Expenditures	$6.195K	$49.16K	$51.76K
Free Cash Flow	-$840.1K	-$767.4K	-$3.579M
YoY Change	11.65%	-6.88%	16.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-01-31
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--01-31
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	000-55654
CY2024	dei	Entity Registrant Name EntityRegistrantName	NUTRIBAND INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-1118176
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	121 South Orange Ave
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1500
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Orlando
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32801
CY2024	dei	City Area Code CityAreaCode	(407)
CY2024	dei	Local Phone Number LocalPhoneNumber	377-6695
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Public Float EntityPublicFloat	17131304	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10969870	shares
CY2024	dei	Auditor Firm AuditorFirmId	3627
CY2024	dei	Auditor Name AuditorName	Sadler, Gibb & Associates, LLC
CY2024	dei	Auditor Location AuditorLocation	Draper, UT
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	492942	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1985440	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	148649	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	113045	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	168605	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	229335	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	211667	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	365925	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	1021863	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	2693745	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	774924	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	897735	usd
CY2024Q1	us-gaap	Goodwill Goodwill	5021713	usd
CY2023Q1	us-gaap	Goodwill Goodwill	5021713	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	31374	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	62754	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	667280	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	780430	usd
CY2024Q1	us-gaap	Assets Assets	7517154	usd
CY2023Q1	us-gaap	Assets Assets	9456377	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	680132	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	534679	usd
CY2024Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	157502	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	162903	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	34276	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	31291	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	127183	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	19740	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	999093	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	748613	usd
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	79826	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	100497	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34277	usd
CY2024Q1	us-gaap	Liabilities Liabilities	1078919	usd
CY2023Q1	us-gaap	Liabilities Liabilities	883387	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	291666666	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	291666666	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8869870	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7843150	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8859870	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7833150	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	8860	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	7833	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	34442339	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31092807	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-304	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-304	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10000	shares
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10000	shares
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	32641	usd
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	32641	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27980019	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22494705	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	6438235	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8572990	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7517154	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9456377	usd
CY2024	us-gaap	Revenues Revenues	2085314	usd
CY2023	us-gaap	Revenues Revenues	2079609	usd
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	1223209	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	1329200	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1960425	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	982227	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	327326	usd
CY2024	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3773606	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3916041	usd
CY2024	us-gaap	Costs And Expenses CostsAndExpenses	6957240	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	6554794	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-4871926	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4475185	usd
CY2024	us-gaap	Interest Income Other InterestIncomeOther	16850	usd
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-554423	usd
CY2024	us-gaap	Interest Expense InterestExpense	75815	usd
CY2023	us-gaap	Interest Expense InterestExpense	8289	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-613388	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8289	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5485314	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4483474	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-5485314	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4483474	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7954105	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8459547	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8572990	usd
CY2024	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	242840	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	499856	usd
CY2024	ntrb	Stock Issued During Period Value Note Payable And Interest StockIssuedDuringPeriodValueNotePayableAndInterest	2607863	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-5485314	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	6438235	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	11859285	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	296875	usd
CY2023	ntrb	Stock Issued During Period Value Treasury Stock Issued For Services StockIssuedDuringPeriodValueTreasuryStockIssuedForServices	113155	usd
CY2023	ntrb	Stock Issued During Period Value Treasury Stock And Warrants Issued For Termination Agreement StockIssuedDuringPeriodValueTreasuryStockAndWarrantsIssuedForTerminationAgreement	174025	usd
CY2023	ntrb	Stock Issued During Period Value Treasury Stock Repurchased StockIssuedDuringPeriodValueTreasuryStockRepurchased	-119006	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	732130	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4483474	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8572990	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-5485314	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4483474	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	287722	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	330143	usd
CY2024	us-gaap	Operating Lease Expense OperatingLeaseExpense	31380	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	38813	usd
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-554423	usd
CY2024	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	118365	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	113155	usd
CY2023	ntrb	Treasury Stock Issued For Termination Agreement TreasuryStockIssuedForTerminationAgreement	174025	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	327326	usd
CY2024	ntrb	Stockbased Compensationwarrants StockbasedCompensationwarrants	242840	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	499856	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	732130	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	153969	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	41665	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-154258	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-4547	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-60730	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	97687	usd
CY2024	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-5401	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	56636	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-31292	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-36287	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	198893	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-104860	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3527509	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2987198	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	51761	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	79304	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-51761	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-79304	usd
CY2024	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	2000000	usd
CY2024	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	106528	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	296875	usd
CY2024	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	19756	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	17795	usd
CY2023	ntrb	Purchase Of Treasury Stock PurchaseOfTreasuryStock	-119006	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2086772	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	160074	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1492498	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2906428	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1985440	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4891868	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	492942	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1985440	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	7352	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	4266	usd
CY2023	ntrb	Adoptionof Operating Lease Assetand Liability AdoptionofOperatingLeaseAssetandLiability	94134	usd
CY2023	ntrb	Promissory Note On Equipment Purchase PromissoryNoteOnEquipmentPurchase	22794	usd
CY2023	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	1400	usd
CY2024	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2607863	usd
CY2018Q3	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	2250000	usd
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	250000	shares
CY2018Q3	ntrb	Royalty Percentage RoyaltyPercentage	0.06	pure
CY2024	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022.
CY2024Q1	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	492942	usd
CY2024	ntrb	Working Capital WorkingCapital	22770	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-4871926	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3527509	usd
CY2021Q4	ntrb	Proceeds From Issuances Initial Public Offering ProceedsFromIssuancesInitialPublicOffering	5836230	usd
CY2021Q4	ntrb	Proceeds From Warrants Exercises ProceedsFromWarrantsExercises	3239845	usd
CY2023Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2000000	usd
CY2023Q3	us-gaap	Separate Account Liability Withdrawal SeparateAccountLiabilityWithdrawal	5000000	usd
CY2024	us-gaap	Repayments Of Advances For Construction RepaymentsOfAdvancesForConstruction	2000000	usd
CY2024Q1	us-gaap	Debt Current DebtCurrent	2000000	usd
CY2024Q1	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	1026720	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	8400000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i><span style="text-decoration:underline">Use of Estimates </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</p>
CY2024	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i><span style="text-decoration:underline">Revenue Recognition </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.</p>
CY2024	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1920280	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1785507	usd
CY2024	us-gaap	Cost Of Services Catering CostOfServicesCatering	165034	usd
CY2023	us-gaap	Cost Of Services Catering CostOfServicesCatering	294102	usd
CY2024	us-gaap	Revenues Revenues	2085314	usd
CY2023	us-gaap	Revenues Revenues	2079609	usd
CY2024	us-gaap	Revenues Revenues	2085314	usd
CY2023	us-gaap	Revenues Revenues	2079609	usd
CY2024Q1	us-gaap	Accounts Receivable Fair Value Disclosure AccountsReceivableFairValueDisclosure	106528	usd
CY2024	ntrb	Loan Bears Interest Percentage LoanBearsInterestPercentage	0.10	pure
CY2024Q1	us-gaap	Other Inventory OtherInventory	168605	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8707	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	134691	usd
CY2023Q1	us-gaap	Other Inventory OtherInventory	229335	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	11021	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	218334	usd
CY2024	ntrb	Estimated Useful Live EstimatedUsefulLive	P10Y
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1456617	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1404856	usd
CY2024Q1	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	681693	usd
CY2023Q1	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	507121	usd
CY2024Q1	ntrb	Goodwill Value GoodwillValue	1719235	usd
CY2020Q3	ntrb	Goodwill Value GoodwillValue	5810640	usd
CY2024Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	3302478	usd
CY2024	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	5021713	usd
CY2023	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	5021713	usd
CY2024Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	2157873	shares
CY2023Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1778006	shares
CY2022Q2	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.0295	pure
CY2022Q2	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	410	usd
CY2022Q2	us-gaap	Line Of Credit Facility Average Outstanding Amount LineOfCreditFacilityAverageOutstandingAmount	15232	usd
CY2022Q2	us-gaap	Line Of Credit Facility Maximum Amount Outstanding During Period LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod	4456	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	774924	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	897735	usd
CY2024	us-gaap	Depreciation Depreciation	174572	usd
CY2023	us-gaap	Depreciation Depreciation	183660	usd
CY2024	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	131360	usd
CY2023	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	139689	usd
CY2024	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1151916	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-941530	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	155966	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	168768	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	68738	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	995950	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	704024	usd
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	15800000	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1151916	usd
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3312698	usd
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2316748	usd
CY2024	ntrb	Stock Issued For Services StockIssuedForServices	-1455848	usd
CY2023	ntrb	Stock Issued For Services StockIssuedForServices	-1299882	usd
CY2024	us-gaap	Asset Impairment Charges AssetImpairmentCharges	-1051714	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	-1051714	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5820260	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4668344	usd
CY2024	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2028-10-16
CY2024	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.05	pure
CY2024	ntrb	Due Balance Amount DueBalanceAmount	85249	usd
CY2024Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	16129	usd
CY2023	us-gaap	Line Of Credit Facility Average Outstanding Amount LineOfCreditFacilityAverageOutstandingAmount	100627	usd
CY2022Q2	us-gaap	Line Of Credit LineOfCredit	32274	usd
CY2022Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	22795	usd
CY2023Q3	us-gaap	Line Of Credit Facility Capacity Available For Trade Purchases LineOfCreditFacilityCapacityAvailableForTradePurchases	5000000	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	374500	shares
	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	374500	shares
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	2.12
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	2.12
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P3Y
CY2023Q1	us-gaap	Line Of Credit Facility Capacity Available For Trade Purchases LineOfCreditFacilityCapacityAvailableForTradePurchases	2000000	usd
CY2024Q1	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.07	pure
CY2023Q1	ntrb	Line Of Credit Facility Converted LineOfCreditFacilityConverted	2000000	usd
CY2023	us-gaap	Line Of Credit Facility Increase Accrued Interest LineOfCreditFacilityIncreaseAccruedInterest	53476	usd
CY2023	ntrb	Line Of Credit Facility Common Stock LineOfCreditFacilityCommonStock	1026520	shares
CY2023	ntrb	Fair Value Of Common Stock FairValueOfCommonStock	2554423	usd
CY2024	us-gaap	Line Of Credit Facility Average Outstanding Amount LineOfCreditFacilityAverageOutstandingAmount	0	usd
CY2024Q1	us-gaap	Notes And Loans Payable NotesAndLoansPayable	106528	usd
CY2024Q1	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.10	pure
CY2024	us-gaap	Interest Expense Debt InterestExpenseDebt	5470	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1131500	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1131500	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	464220	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	351070	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	667280	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	780430	usd
CY2024Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	25000	shares
CY2024	ntrb	Warrants To Purchase WarrantsToPurchase	25000	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.5
CY2023	us-gaap	Interest Expense Deposits InterestExpenseDeposits	33334	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	113150	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	146483	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	113109	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	113109	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	113109	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	113109	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	113109	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	101735	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	667280	usd
CY2024	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	424826	usd
CY2023Q3	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	5000000	usd
CY2023Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	2000000	usd
CY2023Q3	ntrb	Purchase Share PurchaseShare	1	pure
CY2024	us-gaap	Derivative Cash Received On Hedge DerivativeCashReceivedOnHedge	2000000	usd
CY2023Q4	ntrb	Line Of Credit Facility LineOfCreditFacility	2000000	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	1167	shares
CY2022Q2	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	53200	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	137084	shares
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P3Y
CY2022Q3	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	399075	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	35000	shares
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P5Y
CY2022Q3	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	85995	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	107500	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P3Y
CY2022Q4	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	245170	usd
CY2024	ntrb	Common Stock Of Description CommonStockOfDescription	the Company effected a one-for-four reverse stock split, pursuant to which each outstanding share of common stock was changed into 0.25 shares of common stock, and the Company decreased its authorized common stock in the same ratio from 100,000,000 to 25,000,000 shares.
CY2024	ntrb	Stockholder Equity Note Stock Split StockholderEquityNoteStockSplit	the Company approved a 7-for-6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date.
CY2024	us-gaap	Option Indexed To Issuers Equity Shares OptionIndexedToIssuersEquityShares	10000	shares
CY2024Q1	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount	32641	usd
CY2022Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	35584	shares
CY2022Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	35584	shares
CY2022Q1	ntrb	Treasury Stock Purchase TreasuryStockPurchase	119006	usd
CY2022Q2	ntrb	Treasury Stock Purchase TreasuryStockPurchase	119006	usd
CY2022Q2	ntrb	Issuance Of Common Stock IssuanceOfCommonStock	33397	shares
CY2022Q4	ntrb	Issuance Of Common Stock IssuanceOfCommonStock	33397	shares
CY2022Q2	ntrb	Treasury Shares And Recorded Compensation Expense TreasurySharesAndRecordedCompensationExpense	113155	usd
CY2023	us-gaap	Option Indexed To Issuers Equity Shares OptionIndexedToIssuersEquityShares	10000	shares
CY2023Q1	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount	32641	usd
CY2022Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	296875	usd
CY2022Q3	ntrb	Issuance Of Common Stock IssuanceOfCommonStock	55417	shares
CY2022Q3	ntrb	Cancelled Shares CancelledShares	1400000	shares
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	30000	shares
CY2024	ntrb	Options Vest Expire Year OptionsVestExpireYear	P5Y
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	145833	shares
CY2024	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	1.93
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	242840	usd
CY2024	ntrb	Schedule Of Additional Relating Warrants Outstanding ScheduleOfAdditionalRelatingWarrantsOutstanding	The following table summarizes additional information relating to the warrants outstanding as of January 31, 2024:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Range of Exercise<br/> Prices</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number<br/> Outstanding</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted Average<br/> Remaining<br/> Contractual<br/> Life(Years)</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted Average<br/> Exercise Price for <br/> Shares<br/> Outstanding</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number<br/> Exercisable</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted Average<br/> Exercise Price for<br/> Shares<br/> Exercisable</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Intrinsic<br/> Value</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">30,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">4.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">30,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right">6.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,082,205</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,082,205</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right">1.93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">145,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">145,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">99,166</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.77</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><b> </b></p>
CY2021Q4	us-gaap	Shares Issued SharesIssued	408333	shares
CY2022Q1	ntrb	Additional Share AdditionalShare	233333	shares
CY2023Q1	ntrb	Additional Share AdditionalShare	233333	shares
CY2021Q4	ntrb	Common Stock Reserved CommonStockReserved	408333	shares
CY2024Q1	us-gaap	Investment Owned Balance Shares InvestmentOwnedBalanceShares	166	shares
CY2024Q1	us-gaap	Fair Value Option Ineligible Items Aggregate Carrying Amount FairValueOptionIneligibleItemsAggregateCarryingAmount	499856	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y6M
CY2023	ntrb	Purchase Shares PurchaseShares	279584	shares
CY2023	ntrb	Fair Value Options Service Amount FairValueOptionsServiceAmount	732130	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.03	pure
CY2024	us-gaap	Gain Loss On Sales Of Loans Net GainLossOnSalesOfLoansNet	2085314	usd
CY2023	us-gaap	Gain Loss On Sales Of Loans Net GainLossOnSalesOfLoansNet	2079699	usd
CY2024	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	862105	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	750404	usd
CY2024	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	5734031	usd
CY2023	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	5225594	usd
CY2024	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	287722	usd
CY2023	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	330143	usd
CY2024	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2085314	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2079699	usd
CY2024Q1	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	774924	usd
CY2023Q1	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	897735	usd
CY2024Q1	us-gaap	Other Assets OtherAssets	7516854	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	9456377	usd
CY2024	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022
CY2024	ntrb	Percentage Of Net Income PercentageOfNetIncome	0.035	pure
CY2022Q3	ntrb	Agreed To Annual Salary AgreedToAnnualSalary	150000	usd
CY2024	us-gaap	Other Commitments Description OtherCommitmentsDescription	the Company signed a feasibility agreement with Kindeva Drug Delivery, L.P. (“Kindeva”) to develop Nutriband’s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system).
CY2024	srt	Previously Estimated Development Costs Incurred PreviouslyEstimatedDevelopmentCostsIncurred	2500000	usd
CY2022Q1	us-gaap	Deposit Assets DepositAssets	250000	usd
CY2024	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	2369508	usd
CY2024Q1	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	138250	usd
CY2024	ntrb	Estimated Cost EstimatedCost	8100000	usd
CY2022Q1	ntrb	Warehouse Space WarehouseSpace	12000	pure
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3000	usd
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	94134	usd
CY2022Q3	us-gaap	Notes Issued1 NotesIssued1	20000	usd
CY2023Q1	ntrb	Payments For Repurchase Of Warrant PaymentsForRepurchaseOfWarrant	50000	shares
CY2023Q3	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	106528	usd
CY2023Q3	us-gaap	Cash And Due From Banks CashAndDueFromBanks	118675	usd
CY2024	us-gaap	Legal Fees LegalFees	500000	usd
CY2024Q1	us-gaap	Cash Cash	1000000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2023	ntrb	Stock Issued During Period Value Returned In Settlement StockIssuedDuringPeriodValueReturnedInSettlement		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2024	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2024	ntrb	Treasury Stock Issued For Termination Agreement TreasuryStockIssuedForTerminationAgreement		usd
CY2024	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023	ntrb	Stockbased Compensationwarrants StockbasedCompensationwarrants		usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
CY2024	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2024	ntrb	Purchase Of Treasury Stock PurchaseOfTreasuryStock		usd
CY2024	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2024	ntrb	Adoptionof Operating Lease Assetand Liability AdoptionofOperatingLeaseAssetandLiability		usd
CY2024	ntrb	Promissory Note On Equipment Purchase PromissoryNoteOnEquipmentPurchase		usd
CY2024	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
CY2024	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2024	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2024	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses		usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001676047

Files In Submission

Name	View Source	Status
0001213900-24-037996-index-headers.html	Edgar Link	pending
0001213900-24-037996-index.html	Edgar Link	pending
0001213900-24-037996.txt	Edgar Link	pending
0001213900-24-037996-xbrl.zip	Edgar Link	pending
ea0204725-10k_nutriband.htm	Edgar Link	pending
ea020472501ex31-1_nutriband.htm	Edgar Link	pending
ea020472501ex31-2_nutriband.htm	Edgar Link	pending
ea020472501ex32_nutriband.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ntrb-20240131.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
ntrb-20240131_pre.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ntrb-20240131_cal.xml	Edgar Link	unprocessable
ntrb-20240131_def.xml	Edgar Link	unprocessable
ntrb-20240131_lab.xml	Edgar Link	unprocessable
ea0204725-10k_nutriband_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NTRB
NutriBand Inc. Stock $ntrb

2024 Q2 Form 10-K Financial Statement

#000121390024037996 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NTRB NutriBand Inc. Stock $ntrb

2024 Q2 Form 10-K Financial Statement

#000121390024037996 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NTRB
NutriBand Inc. Stock $ntrb